Tezosentan did not improve breathlessness or cardiovascular events

Tezosentan is an intravenous short-acting endothelin receptor antagonist (a drug that neutralizes or counteracts the effects of another drug) and a vasodilator (a drug that causes dilation of blood vessels).
The researchers found that tezosentan did not improve dyspnea (difficulty breathing) more than placebo in either trial. The incidence of death or worsening heart failure at seven days in the combined trials was 26 percent in each treatment group, and up to 30 days was 32 percent in the tezosentan group and 33 percent in the placebo group. The number of deaths at six months was 104 (14.3 percent) in the tezosentan group and 101 (14.3 percent) in the placebo group.